Sameh Mobarek, MD
Clinical Cardiac Electrophysiology · Cary, NCNPI 1609874130
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $89,602 of the $120,454 with a category attached, or 74.4%. 22 manufacturers reported payments, led by Lundbeck LLC at 46.4% of the total. Reporting peaked in 2019 at $104,178 and has fallen 99.8% since, to $186 in 2025. Among clinical cardiac electrophysiology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 235 payments — averaging $512.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$56K
- Johnson & Johnson$44K
- Novartis$9K
- Medtronic$9K
- Cordis US CORP.$500
- Irhythm Technologies, Inc.$293
- plus $1K from 16 others
Across 8 payments — averaging $1383.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Impulse Dynamics (USA) Inc.$8K
- Boston Scientific$3K
What the payments were for
- Consulting fees$8001%
- Speaking & faculty fees$89,60274%
- Grants$1000%
- Travel & lodging$23,84620%
- Food & beverage$6,0725%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 68 | $55,833 |
| Johnson & Johnson | 45 | $44,285 |
| Novartis | 11 | $9,316 |
| Medtronic(2 entities) | 72 | $9,074 |
| Cordis US CORP. | 1 | $500 |
| Irhythm Technologies, Inc. | 9 | $293 |
| Esperion Therapeutics, Inc. | 4 | $269 |
| Impulse Dynamics (USA) Inc. | 4 | $172 |
| Axsome Therapeutics, Inc. | 3 | $134 |
| Akcea Therapeutics, Inc. | 1 | $125 |
| Abiomed | 1 | $93 |
| Sanofi-aventis U.S. LLC | 1 | $93 |
| Alnylam Pharmaceuticals Inc. | 1 | $72 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $31 |
| Amgen | 1 | $24 |
| Elutia, Inc. | 5 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Merck | 1 | $22 |
| Kestra Medical Technology Services, Inc. | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Davol Inc. | 1 | $18 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NORTHERA$46,095
- XARELTO$43,684
- ENTRESTO$9,082
- AURORA EV-ICD MRI SURESCAN$1,484
- Micra$1,098
- EVERA MRI XT DR SURESCAN$810
- MYNX CONTROL$500
- NEXLIZET$230
- NEXLETOL$230
- OPTIMIZER$217
- TEGSEDI$125
- SUNOSI$107
How this compares
$120,454 in reported general payments places this provider in the 90th percentile of 98 clinical cardiac electrophysiology providers in North Carolina.
See all clinical cardiac electrophysiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 581 | $569,274 |
| XareltoRivaroxaban | 178 | $197,920 |
| EntrestoSacubitril/Valsartan | 131 | $124,369 |
| Droxidopa | 123 | $31,327 |
| MultaqDronedarone Hcl | 18 | $29,191 |
| Dofetilide | 143 | $28,641 |
| NortheraDroxidopa | 11 | $26,267 |
| Repatha SureclickEvolocumab | 22 | $26,160 |
| JardianceEmpagliflozin | 18 | $15,243 |
| Midodrine Hcl | 143 | $11,445 |
| FarxigaDapagliflozin Propanediol | 14 | $11,036 |
| Flecainide Acetate | 233 | $10,895 |
| CorlanorIvabradine Hcl | 20 | $9,057 |
| Sodium Chloride0.9 % Sodium Chloride | 153 | $6,253 |
| Pyridostigmine Bromide | 105 | $5,526 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $569,274581 claims |
| Johnson & JohnsonXarelto | $44,285 | $197,920178 claims |
| NovartisEntresto | $9,316 | $124,369131 claims |
| Sanofi-aventis U.S. LLCMultaq | $93 | $29,19118 claims |
| Lundbeck LLCNorthera | $55,833 | $26,26711 claims |
| AmgenCorlanor | $24 | $9,05720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 98 clinical cardiac electrophysiology providers in North Carolina.
Other clinical cardiac electrophysiology in Cary
- Pavlo NetrebkoCary$17K
- Michael ManogueAsheville$230K
- Daniel FriedmanDurham$196K
- James AllredGreensboro$184K
- John RhynerAsheville$168K
- Gregory HarrisGreenville$164K
- John CatanzaroGreenville$159K
- Kevin ManochaRaleigh$146K
- Albert SunDurham$138K
- Manish JainConcord$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.